Tvardi Therapeutics (NASDAQ:TVRD) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Tvardi Therapeutics (NASDAQ:TVRD) from a hold rating to a sell rating in a research note published on Friday.

TVRD has been the subject of several other reports. Cantor Fitzgerald cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Piper Sandler downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. BTIG Research dropped their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, October 13th. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Finally, Raymond James Financial lowered shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $55.50.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD opened at $4.69 on Friday. The firm has a market cap of $43.99 million, a PE ratio of -0.49 and a beta of 0.09. The firm’s 50 day simple moving average is $4.21 and its 200-day simple moving average is $16.74. Tvardi Therapeutics has a one year low of $3.74 and a one year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of large investors have recently bought and sold shares of TVRD. Geode Capital Management LLC purchased a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $2,617,000. JPMorgan Chase & Co. purchased a new position in shares of Tvardi Therapeutics during the second quarter worth $39,000. New York State Common Retirement Fund purchased a new position in shares of Tvardi Therapeutics during the second quarter worth $92,000. Marshall Wace LLP acquired a new position in Tvardi Therapeutics during the second quarter valued at $583,000. Finally, Slate Path Capital LP purchased a new stake in Tvardi Therapeutics in the second quarter valued at $16,427,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.